NEET-PG 2013 Practice Questions

Q: Which one of the following is the most common CNS tumor associated with type I neurofibromatosis?

Optic nerve glioma. ***Optic nerve glioma*** - **Optic nerve gliomas** are the most frequently encountered central nervous system tumors in patients with **Type 1 neurofibromatosis (NF1)**, occurring in about 15% of individuals. - They are typically low-grade **astrocytomas** and can cause vision loss and proptosis depending on their size and location. *Meningioma* - While more common in **Type 2 neurofibromatosis (NF2)**, meningiomas can occur in NF1, but are not the most common CNS tumor. - Meningiomas are tumors that arise from the **meninges**, the membranes surrounding the brain and spinal cord. *Acoustic schwannoma* - **Bilateral acoustic schwannomas (vestibular schwannomas)** are the hallmark feature of **Type 2 neurofibromatosis (NF2)**, not NF1 [1]. - These tumors arise from the Schwann cells of the **vestibulocochlear nerve** and can cause hearing loss and balance issues [1]. *Low grade astrocytoma* - While optic nerve gliomas are a type of low-grade astrocytoma, this option is too general; **optic nerve glioma** is the specific and most common presentation in NF1. - Other forms of low-grade astrocytomas can occur in NF1 but are not as universally characteristic as optic nerve gliomas.

Q: Which of the following glands is NOT typically involved in Multiple Endocrine Neoplasia type II A (MEN II A)?

Pituitary gland. ***Pituitary gland*** - The **pituitary gland** is not a characteristic component of **MEN II A**. It is, however, associated with **Multiple Endocrine Neoplasia type I (MEN I)**, which involves the 3 Ps: **pituitary**, **parathyroid**, and **pancreas** [1]. - **MEN IIA** classically involves **medullary thyroid carcinoma**, **pheochromocytoma**, and **parathyroid hyperplasia** [1]. *Thyroid gland* - The **thyroid gland** is centrally involved in MEN IIA, specifically through the development of **medullary thyroid carcinoma (MTC)**, a hallmark feature. - MTC arises from the parafollicular C cells of the thyroid and secretes **calcitonin**. *Parathyroid gland* - The **parathyroid gland** is often involved in MEN IIA, typically presenting as **parathyroid hyperplasia** or adenoma, leading to **primary hyperparathyroidism**. - This typically results in elevated **parathyroid hormone** levels and **hypercalcemia**. *Adrenal gland* - The **adrenal gland** is a key player in MEN IIA due to the occurrence of **pheochromocytoma**, a tumor of the adrenal medulla. - Pheochromocytomas can be bilateral and secrete **catecholamines**, leading to hypertension and other symptoms.

Q: Response to iron therapy in iron deficiency anemia is denoted by?

Reticulocytosis. Reticulocytosis - Reticulocytosis is one of the earliest signs of a positive response to iron therapy in iron deficiency anemia, occurring within 5-10 days. - It signifies that the bone marrow is effectively producing new red blood cells after iron supplementation. Restoration of enzymes - While iron is a crucial component of many enzymes (e.g., catalase, cytochrome oxidase), its restoration takes time and is not the primary immediate indicator of therapeutic response. - Clinical improvement and other hematological parameters precede the full restoration of enzyme function. Increase in hemoglobin - An increase in hemoglobin is a definitive sign of successful treatment, but it occurs later than reticulocytosis, typically visible after several weeks to months of therapy. - Hemoglobin levels rise as the new, iron-sufficient red blood cells fully mature and replace the older, iron-deficient ones. Increase in iron binding capacity - In iron deficiency anemia, total iron-binding capacity (TIBC) is typically increased due to more transferrin being available to bind iron [1]. - Successful iron therapy would lead to a decrease in TIBC as transferrin sites become saturated with iron, not an increase.

Q: Cryoprecipitate is useful in which of the following conditions?

Afibrinogenemia. ***Afibrinogenemia*** - Cryoprecipitate is rich in **fibrinogen**, factor VIII, factor XIII, von Willebrand factor, and fibronectin. It is the only blood product with a substantial concentration of fibrinogen. - **Afibrinogenemia** (or hypofibrinogenemia) is a condition characterized by low or absent levels of fibrinogen, a critical clotting factor that cryoprecipitate replaces effectively. *Hemophilia A* - Hemophilia A is a deficiency of **Factor VIII**. While cryoprecipitate contains factor VIII, **recombinant Factor VIII concentrates** are the preferred treatment due to better safety (reduced risk of viral transmission) and more precise dosing [1]. - Cryoprecipitate was historically used for Hemophilia A before the availability of safer, more specific factor concentrates [2]. *Thrombosthenia* - Thrombasthenia is a platelet function disorder characterized by defective **glycoprotein IIb/IIIa receptors** on platelets, leading to impaired platelet aggregation. - Cryoprecipitate does not contain platelets or factors that directly correct platelet function, making **platelet transfusions** the treatment of choice for severe bleeding in thrombasthenia. *Warfarin reversal* - Warfarin reversal is primarily achieved using **Vitamin K**, which restores levels of functional clotting factors II, VII, IX, and X. - For rapid reversal in emergencies, **prothrombin complex concentrate (PCC)** is preferred because it contains high concentrations of these vitamin K-dependent factors, addressing the primary deficiency caused by warfarin [1].

Q: Which of the following is NOT a feature of Peutz-Jeghers syndrome?

Autosomal recessive inheritance. ***High risk of malignancy*** - Peutz-Jeghers syndrome is primarily associated with **benign hamartomatous polyps**, not a **high risk of malignancy**, which distinguishes it from other syndromes. - Although patients may develop cancers [1], the syndrome itself does not inherently denote a high malignancy risk like other syndromes such as familial adenomatous polyposis. *Autosomal dominant* - This syndrome is indeed **autosomal dominant**, caused by mutations in the STK11 gene. - Families with this condition typically show **vertical transmission**, characteristic of autosomal dominant inheritance. *Hamartomatous polyp* - Individuals with Peutz-Jeghers syndrome develop **hamartomatous polyps**, which are a hallmark feature of the condition [1]. - These polyps can occur in the gastrointestinal tract and are benign lesions rather than adenomatous type seen in other syndromes [1]. *Mucocutaneous pigmentation* - Mucocutaneous pigmentation, such as **freckling around the lips and buccal mucosa**, is a key clinical feature of Peutz-Jeghers syndrome. - This pigmentation usually appears in childhood and is often a distinguishing sign of the syndrome.

Q: Hurthle cell carcinoma is a variant of which type of carcinoma?

Follicular carcinoma. **Follicular carcinoma** - **Hürthle cell carcinoma**, also known as **oxyphilic follicular carcinoma**, is a specific variant of **follicular carcinoma of the thyroid**. - It is characterized by the presence of large polygonal cells with abundant eosinophilic, granular cytoplasm known as **Hürthle cells** (or oxyphil cells) within the neoplastic growth. *Medullary carcinoma* - **Medullary carcinoma** originates from the **parafollicular C cells** of the thyroid, which produce calcitonin. - It is histologically distinct, featuring nests or cords of cells often associated with **amyloid deposits**, and is not related to Hürthle cell morphology. *Papillary carcinoma* - **Papillary carcinoma** is the most common type of thyroid cancer, characterized by distinctive **nuclear features** such as **Orphan Annie eye nuclei**, nuclear grooves, and intranuclear cytoplasmic inclusions. - Its histological origin and morphological appearance are different from Hürthle cell neoplasms, which are follicular in origin. *Anaplastic carcinoma* - **Anaplastic carcinoma** is a highly aggressive and undifferentiated thyroid malignancy with a very poor prognosis. - It is characterized by pleomorphic, giant, and spindle cells and lacks the specific differentiation seen in follicular or Hürthle cell tumors.

Q: Which of the following is not a germ cell tumor?

Leydig cell tumor. ***Leydig cell tumor*** - Leydig cell tumors are classified as **sex-cord stromal tumors**, not germ cell tumors [1]. - These tumors are derived from **Leydig cells** which produce androgens, affecting the endocrine function rather than germ cell lineage [1]. *Endodermal sinus* - Endodermal sinus tumors, or **yolk sac tumors**, are indeed germ cell tumors characterized by **alpha-fetoprotein (AFP)** production [2]. - They typically arise in the testis or ovaries and are known for rapid growth and aggressiveness. *Embryonal carcinoma* - Embryonal carcinoma is a type of **germ cell tumor** commonly associated with elevated levels of **beta-hCG** [2]. - It primarily affects the testes in males and can occur in the ovaries, and it is known for its aggressive behavior. *Seminoma* - Seminomas are classic examples of **germ cell tumors**, noted for their sensitivity to radiation and chemotherapy [3]. - They usually present with **increased beta-hCG** levels and can coexist with non-seminomatous germ cell tumors [3]. **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Diseases Of The Urinary And Male Genital Tracts, pp. 510-514. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Lower Urinary Tract and Male Genital System, pp. 979-980. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Lower Urinary Tract and Male Genital System, pp. 980-982.

Q: Peliosis hepatis is caused by all except?

Analgesics. ***Analgesics*** - While various drugs can cause liver injury, **analgesics** are not typically associated with the development of **peliosis hepatis**. [1] - **Peliosis hepatis** involves blood-filled cysts in the liver and is linked to specific agents, not common pain relievers. *Anabolic steroids* - **Anabolic steroids** are a well-known cause of **peliosis hepatis**, especially with prolonged high-dose use. - They can induce sinusoidal dilation and hemorrhage, leading to **blood-filled cysts** in the liver. *OC pills* - **Oral contraceptive pills** (OCPs) containing estrogen have been implicated in the development of **peliosis hepatis**, though it is rare. - The estrogen component is thought to affect the **vascular endothelium** and sinusoidal integrity of the liver. *Danazol* - **Danazol**, an attenuated androgen, is strongly associated with **peliosis hepatis** and other liver complications. - It can cause severe damage to the **hepatic sinusoids**, leading to the characteristic blood-filled cavities. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Liver and Gallbladder, pp. 847-848.

Q: Which of the following statements is true regarding omalizumab?

All of the options. ***All of the options*** is correct because each statement is true: **Anti-IgE** - Omalizumab is a **humanized monoclonal antibody** that specifically targets and binds to **free IgE** in the circulation - By binding free IgE, it prevents IgE from attaching to **high-affinity receptors** on mast cells and basophils - This reduces the allergic cascade and prevents release of inflammatory mediators **Given subcutaneously** - Omalizumab is administered via **subcutaneous injection** only - Dosing is typically every **2 to 4 weeks** based on patient's body weight and baseline IgE levels - Not available in oral or intravenous formulations for asthma treatment **Used as add-on therapy in moderate to severe asthma prophylaxis** - FDA approved as **add-on maintenance treatment** for patients aged ≥6 years with **moderate to severe persistent allergic asthma** - Indicated when asthma is **inadequately controlled** with inhaled corticosteroids - Reduces frequency of asthma exacerbations and improves asthma control - Also approved for chronic spontaneous urticaria All three statements accurately describe omalizumab's mechanism, administration route, and clinical indication, making **"All of the options"** the correct answer.

Q: Which route of administration undergoes the maximum first pass metabolism?

Oral. ***Oral*** - Drugs administered orally are absorbed from the **gastrointestinal tract** and transported via the **portal vein** directly to the liver, where they undergo significant **first-pass metabolism** before reaching systemic circulation. - This hepatic metabolism can drastically reduce the **bioavailability** of the drug, requiring higher doses or alternative administration routes. *Intra-arterial* - This route delivers drugs directly into an **artery** supplying a target tissue or organ, largely bypassing systemic circulation and initial hepatic metabolism. - It is used for localized effects, such as **chemotherapy** for specific tumors, minimizing systemic exposure. *Rectal* - While a portion of rectally administered drugs may bypass the portal circulation by entering the **inferior and middle rectal veins**, a significant amount can still be absorbed into the superior rectal vein, which drains into the portal system. - This means rectal administration offers only **partial avoidance** of first-pass metabolism, making it less complete than IV or intra-arterial routes for bypassing the liver altogether. *Intravenous* - Drugs administered intravenously are delivered directly into the **systemic circulation**, completely bypassing the gastrointestinal tract and the liver's first-pass metabolism. - This route ensures **100% bioavailability** and rapid onset of action, as the drug immediately reaches its target.

Question 1

Which one of the following is the most common CNS tumor associated with type I neurofibromatosis?

Accepted Answer

Optic nerve glioma

Answer

Meningioma

Answer

Acoustic schwannoma

Answer

Low grade astrocytoma

Question 2

Which of the following glands is NOT typically involved in Multiple Endocrine Neoplasia type II A (MEN II A)?

Accepted Answer

Pituitary gland

Answer

Thyroid gland

Answer

Parathyroid gland

Answer

Adrenal gland

Question 3

Response to iron therapy in iron deficiency anemia is denoted by?

Accepted Answer

Reticulocytosis

Answer

Increase in hemoglobin

Answer

Restoration of enzymes

Answer

Increase in iron binding capacity

Question 4

Cryoprecipitate is useful in which of the following conditions?

Accepted Answer

Afibrinogenemia

Answer

Hemophilia A

Answer

Thrombosthenia

Answer

Warfarin reversal

Question 5

Which of the following is NOT a feature of Peutz-Jeghers syndrome?

Accepted Answer

Autosomal recessive inheritance

Answer

Mucocutaneous pigmentation

Answer

Autosomal dominant

Answer

Hamartomatous polyp

Question 6

Hurthle cell carcinoma is a variant of which type of carcinoma?

Accepted Answer

Follicular carcinoma

Answer

Medullary carcinoma

Answer

Papillary carcinoma

Answer

Anaplastic carcinoma

Question 7

Which of the following is not a germ cell tumor?

Accepted Answer

Leydig cell tumor

Answer

Embryonal carcinoma

Answer

Endodermal sinus

Answer

Seminoma

Question 8

Peliosis hepatis is caused by all except?

Accepted Answer

Analgesics

Answer

OC pills

Answer

Danazol

Answer

Anabolic steroids

Question 9

Which of the following statements is true regarding omalizumab?

Accepted Answer

All of the options

Answer

Anti-IgE

Answer

Given subcutaneously

Answer

Used as add-on therapy in moderate to severe asthma prophylaxis

Question 10

Which route of administration undergoes the maximum first pass metabolism?

Accepted Answer

Oral

Answer

Intra-arterial

Answer

Rectal

Answer

Intravenous

NEET-PG 2013

Internal Medicine

Pathology

Pharmacology